In addition, Aureus plans to deliver its high-quality content in MDL® Direct format. This will accelerate drug discovery workflows for MDL Isentris customers by enabling them to access Aureus content via the MDL® Isentris® informatics system.
Chemistry and biology content from Aureus includes detailed experimental activity data mined from the literature related to important drug classes (including GPCRs, ion channels and kinases) as well as other drug safety topics (ADME/drug-drug interactions and the hERG channel).
The partnership agreement permits Aureus Pharma to augment its own commercial knowledge databases with the industry-leading chemical representation and reaction searching performance of the MDL® Direct data cartridge.
The MDL Direct chemistry search engine accelerates R&D workflows by combining full reaction transformation searching, unsurpassed chemistry sophistication and proven performance on databases with over five million reactions and at least 20 million structures.
"Using the capabilities of MDL Isentris to integrate Aureus Pharma's comprehensive chemistry and biology content management system with other proprietary and commercial information will accelerate knowledgedriven discovery," said Jason Theodosiou, CEO of Aureus Pharma.
“We are especially pleased by the opportunity to enhance the usability and performance of our knowledge databases with MDL Direct cartridge technology,” Theodosiou added.
“Aureus Pharma joins a growing community of informatics companies that is working with Elsevier MDL to offer scientists comprehensive content solutions through the integrating Isentris system,” commented Lars Barfod, President and CEO of Elsevier MDL.
“Making Aureus’s extensive chemical and biological data available via Isentris reinforces our promise to the market that Isentris offers researchers critical multidisciplinary content across the discovery spectrum.”